Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Clinical trial assessing safety and efficacy of paxalisib in combination with KEYTRUDA® (pembrolizumab) or LYNPARZA® (olaparib) in women with triple negative breast cancer.

Next Previous
Trial Profile

Phase 1 Clinical trial assessing safety and efficacy of paxalisib in combination with KEYTRUDA® (pembrolizumab) or LYNPARZA® (olaparib) in women with triple negative breast cancer.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paxalisib (Primary) ; Carboplatin; Gemcitabine; Olaparib; Paclitaxel; Pembrolizumab
  • Indications Advanced breast cancer; Triple negative breast cancer
  • Focus Adverse reactions
  • Acronyms ABC-Pax

Most Recent Events

  • 16 Jul 2025 According to Kazia therapeutics media release, the company announced preliminary results from the first patient in this trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda), and standard chemotherapy after completing Cycle 1 (21 days) of dosing.
  • 05 Jun 2025 According to Kazia therapeutics media release, first patient has been dosed in this study.
  • 15 May 2025 According to Kazia therapeutics media release, the trial is actively screening patients at The Royal Brisbane and Womens Hospital, Gold Coast University Hospital and Sunshine Coast University Hospital in Queensland, Australia with plans to open up to 4 additional sites in Australia.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top